NeoGenomics: On a Recovery Path Thanks to New Liquid Biopsy Test and Patent Win
Reading Time: 3 minutes
The stock of the provider of oncology diagnostic tests and consulting services has been in a steep downward trend since the end of 2024, following several years of sideways movement. Since the end of July, the price has recovered and has since risen by over 120%. As a result, the stock is again halfway towards its 3-year high, which is dated for December 2023. Since the end of July 2025, two new product launches and a won legal dispute have been the main drivers of the price recovery. The beginning of the recovery of the stock price coincides...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
